William G Blum

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes
    William Blum
    Division of Hematology, Department of Medicine, The Ohio State University and Comprehensive Cancer Center, Columbus, OH 43210, USA
    Hematology Am Soc Hematol Educ Program 2010:314-21. 2010
  2. ncbi Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
    William Blum
    Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, B310 Starling Loving Hall, Columbus, OH 43210, USA
    Blood 119:6025-31. 2012
  3. ncbi Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
    William Blum
    Division of Hematology and Oncology, Department of Medicine, and Center for Biostatistics, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 107:7473-8. 2010
  4. ncbi New approaches in acute myeloid leukemia
    William Blum
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Best Pract Res Clin Haematol 21:29-41. 2008
  5. ncbi Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
  6. ncbi Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome
    William Blum
    Department of Internal Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, Ohio 43210, USA
    Semin Thromb Hemost 33:350-4. 2007
  7. ncbi Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology and Oncology and the Comprehensive Cancer Center, Department of Medicine, The Ohio State University, B310 Starling Loving Hall, 320 West 10 Avenue, Columbus, OH 43210, USA
    Haematologica 95:1098-105. 2010
  8. ncbi Dose escalation of lenalidomide in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 28:4919-25. 2010
  9. ncbi Targeting epigenetic changes in acute myeloid leukemia
    William Blum
    The Ohio State University, Columbus, Ohio, USA
    Clin Adv Hematol Oncol 3:855-65, 882. 2005
  10. ncbi High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, Starling Loving Hall, Columbus, OH 43210, USA
    Leuk Res 31:1069-75. 2007

Research Grants

  1. Experimental Therapeutics in Acute Leukemias
    William Blum; Fiscal Year: 2007

Collaborators

Detail Information

Publications33

  1. ncbi How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes
    William Blum
    Division of Hematology, Department of Medicine, The Ohio State University and Comprehensive Cancer Center, Columbus, OH 43210, USA
    Hematology Am Soc Hematol Educ Program 2010:314-21. 2010
    ....
  2. ncbi Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
    William Blum
    Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, B310 Starling Loving Hall, Columbus, OH 43210, USA
    Blood 119:6025-31. 2012
    ..This study demonstrates the feasibility and preliminary clinical activity of decitabine plus bortezomib in AML and identifies FLT3 as a novel pharmacodynamic end point for future trials...
  3. ncbi Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
    William Blum
    Division of Hematology and Oncology, Department of Medicine, and Center for Biostatistics, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 107:7473-8. 2010
    ..Levels of miR-29b should be validated as a predictive factor for stratification of older AML patients to decitabine treatment...
  4. ncbi New approaches in acute myeloid leukemia
    William Blum
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Best Pract Res Clin Haematol 21:29-41. 2008
    ..The following is an outline of several key areas of ongoing AML research...
  5. ncbi Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
    ..To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)...
  6. ncbi Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome
    William Blum
    Department of Internal Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, Ohio 43210, USA
    Semin Thromb Hemost 33:350-4. 2007
    ..This review provides an overview of the pathophysiology of leukostasis and its management with leukapheresis. The use of TPE in the management of hyperviscosity syndrome is also discussed...
  7. ncbi Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology and Oncology and the Comprehensive Cancer Center, Department of Medicine, The Ohio State University, B310 Starling Loving Hall, 320 West 10 Avenue, Columbus, OH 43210, USA
    Haematologica 95:1098-105. 2010
    ....
  8. ncbi Dose escalation of lenalidomide in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 28:4919-25. 2010
    ..Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia...
  9. ncbi Targeting epigenetic changes in acute myeloid leukemia
    William Blum
    The Ohio State University, Columbus, Ohio, USA
    Clin Adv Hematol Oncol 3:855-65, 882. 2005
    ..In this review, we focus on the clinical applicability of epigenetic targeting in the treatment of patients with AML...
  10. ncbi High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, Starling Loving Hall, Columbus, OH 43210, USA
    Leuk Res 31:1069-75. 2007
    ..BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM...
  11. ncbi Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:2364-73. 2008
    ..Our results unveil the Sp1/NF-kappaB pathway as a modulator of DNA methyltransferase activity in human cancer and identify bortezomib as a novel epigenetic-targeting drug...
  12. ncbi TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study
    Klaus H Metzeler
    The Ohio State University Comprehensive Cancer Center, 1216 James Cancer Hospital, 300 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 29:1373-81. 2011
    ....
  13. ncbi Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality
    Naeem A Ali
    Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Cancer 110:96-102. 2007
    ..The authors hypothesized that hyperglycemia may be associated with adverse outcomes in patients with acute myeloid leukemia (AML) and sought to determine whether this association exists in this population...
  14. ncbi Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method
    Zhongfa Liu
    College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Nucleic Acids Res 35:e31. 2007
    ..Our data support the use of our LC-MS/MS method for clinical pharmacodynamic determination of changes in GDM in vivo...
  15. ncbi Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity
    Guido Marcucci
    Division of Hematology Oncology, The Comprehensive Cancer Center, The Ohio State University, 433A Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:3404-11. 2005
    ..Herein, we investigated the feasibility of this approach in untreated elderly AML patients by administering oblimersen sodium (G3139), an 18-mer phosphorothioate antisense to Bcl-2, during induction and consolidation treatments...
  16. ncbi Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature
    William Blum
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus 43210, USA
    Cancer 101:1420-7. 2004
    ..Acute myeloid leukemia (AML) with t(6;11)(q27;q23) is a well established but rare entity, and few studies have reported the full clinical, hematologic, and outcome data of patients with this disease...
  17. ncbi MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
    Ramiro Garzon
    Department of Medicine, Ohio State University, Columbus, 43210, USA
    Blood 113:6411-8. 2009
    ....
  18. ncbi Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
    Rosa Lapalombella
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 112:5180-9. 2008
    ..In addition, they suggest that lenalidomide therapy might be useful to enhance targeted delivery of RNAi-based therapies using CD20 immunoliposomes in B-cell malignancies...
  19. ncbi Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide
    Christopher L Hallemeier
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 12:749-57. 2006
    ..In patients with MDS, this is an effective RIC regimen for allogeneic transplantation that can be used as an alternative to other RIC or conventional conditioning regimens...
  20. ncbi Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13
    Todd A Fehniger
    Department of Internal Medicine, Division of Oncology, Siteman Cancer Center, Washington University, St Louis, MO, USA
    Blood 113:1002-5. 2009
    ..The clinical trials described in this paper have been registered with www.clinicaltrials.gov under identifiers NCT00466895 and NCT00546897...
  21. ncbi Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide
    Mark Girgis
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110-1093, USA
    Blood 105:3035-41. 2005
    ..This regimen resulted in 100% DC in most patients undergoing URD BMT with a relatively low risk for fatal organ toxicity and TRM...
  22. ncbi High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation
    William Blum
    Division of Hematology and Oncology and Comprehensive Cancer Center, The Ohio State University Hospitals, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:61-7. 2006
    ....
  23. ncbi Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells
    Shujun Liu
    Division of Hematology, The Ohio State University, 320 West 10th Avenue, Columbus, OH 43210, USA
    J Pharmacol Exp Ther 321:953-60. 2007
    ....
  24. ncbi Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
    Leslie A Andritsos
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Clin Oncol 26:2519-25. 2008
    ..Herein, we highlight life-threatening tumor flare when higher doses of lenalidomide are administered to patients with CLL and provide a potential mechanism for its occurrence...
  25. ncbi Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
    Mehdi Hamadani
    Division of Hematology and Oncology, Arthur G James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Biol Blood Marrow Transplant 14:783-9. 2008
    ..The addition of infliximab to standard GVHD prophylaxis did not lower the risk of GVHD and was associated with an increased risk of bacterial and invasive fungal infections...
  26. ncbi RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans
    Anja Troeger
    Division of Hematology Oncology, Children s Hospital Boston, 300 Longwood Ave, Boston, MA 02115, USA
    Blood 119:4708-18. 2012
    ....
  27. ncbi Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
    Mehdi Hamadani
    Division of Hematology Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:1422-30. 2009
    ....
  28. ncbi Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
    Rosa Lapalombella
    Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 115:2619-29. 2010
    ..This study is registered at http://clinicaltrials.gov as NCT00466895...
  29. ncbi Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas
    Mehdi Hamadani
    Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:547-53. 2009
    ..Given the outcomes seen here in the setting of PD, such patients should proceed with transplant only in the setting of investigational therapy...
  30. ncbi A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels
    Ping Chen
    College of Pharmacy, The Ohio State University, 500 W 12th Avenue, Columbus, OH 43210, USA
    Pharm Res 26:1504-15. 2009
    ..To simultaneously quantify intracellular nucleoside triphosphate (NTP) and deoxynucleoside triphosphate (dNTP) pools and to assess their changes produced by interfering with ribonucleotide reductase (RNR) expression in leukemia cells...
  31. ncbi A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices
    Xiaohui Wei
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Pharm Res 23:1251-64. 2006
    ..This method provides a powerful technique to evaluate plasma pharmacokinetics and intracellular uptake of PS ODNs in patients and shows its utility in clinical evaluations...
  32. ncbi Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS
    Hao Cheng
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, OH 43210, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 850:206-12. 2007
    ..This method has been applied to the analysis of plasma samples obtained from patients treated with this drug...
  33. ncbi Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia
    Rebecca B Klisovic
    Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 14:3889-95. 2008
    ....

Research Grants2

  1. Experimental Therapeutics in Acute Leukemias
    William Blum; Fiscal Year: 2007
    ..The mentors for the candidate's career development are Dr. Clara Bloomfield, Dr. John Byrd, and Dr. Guido Marcucci at The Ohio State University. They will be assisted in laboratory mentoring by Dr. Denis Guttridge and Dr. James Dalton. ..